Humanigen Inc (HGENQ)

[Fezziwig2008]

HGEN - “National Institutes of Health Selects Humanigen’s Lenzilumab for its COVID-19 Big Effect Trial
Big Effect Trial (BET) sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) to advance high priority therapeutic candidates for COVID-19
Lenzilumab will be evaluated in combination with remdesivir and compared to placebo and remdesivir- “We are thrilled that NIH selected lenzilumab to be part of its Big Effect Trial,” said Cameron Durrant, MD, MBA, chief executive officer of Humanigen. “With data from the BET and our ongoing Phase III study, we will have data from approximately 500 hospitalized COVID-19 patients.” https://www.businesswire.com/news/home/20200727005674/en/National-Institutes-Health-Selects-Humanigen’s-Lenzilumab-COVID-19